405 related articles for article (PubMed ID: 25002527)
1. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Ye P; Mimura J; Okada T; Sato H; Liu T; Maruyama A; Ohyama C; Itoh K
Mol Cell Biol; 2014 Sep; 34(18):3421-34. PubMed ID: 25002527
[TBL] [Abstract][Full Text] [Related]
2. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
Habib E; Linher-Melville K; Lin HX; Singh G
Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
[TBL] [Abstract][Full Text] [Related]
3. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
[TBL] [Abstract][Full Text] [Related]
4. ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner.
Chen D; Fan Z; Rauh M; Buchfelder M; Eyupoglu IY; Savaskan N
Oncogene; 2017 Oct; 36(40):5593-5608. PubMed ID: 28553953
[TBL] [Abstract][Full Text] [Related]
5. Gamma-tocopheryl quinone, not alpha-tocopheryl quinone, induces adaptive response through up-regulation of cellular glutathione and cysteine availability via activation of ATF4.
Ogawa Y; Saito Y; Nishio K; Yoshida Y; Ashida H; Niki E
Free Radic Res; 2008 Jul; 42(7):674-87. PubMed ID: 18654882
[TBL] [Abstract][Full Text] [Related]
6. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
[TBL] [Abstract][Full Text] [Related]
7. Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells.
Starheim KK; Holien T; Misund K; Johansson I; Baranowska KA; Sponaas AM; Hella H; Buene G; Waage A; Sundan A; Bjørkøy G
Blood Cancer J; 2016 Jul; 6(7):e446. PubMed ID: 27421095
[TBL] [Abstract][Full Text] [Related]
8. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
9. Implication of Nrf2 and ATF4 in differential induction of CHOP by proteasome inhibition in thyroid cancer cells.
Zong ZH; Du ZX; Li N; Li C; Zhang Q; Liu BQ; Guan Y; Wang HQ
Biochim Biophys Acta; 2012 Aug; 1823(8):1395-404. PubMed ID: 22691366
[TBL] [Abstract][Full Text] [Related]
10. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
[TBL] [Abstract][Full Text] [Related]
11. Activated Integrated Stress Response Induced by Salubrinal Promotes Cisplatin Resistance in Human Gastric Cancer Cells via Enhanced xCT Expression and Glutathione Biosynthesis.
Wang SF; Wung CH; Chen MS; Chen CF; Yin PH; Yeh TS; Chang YL; Chou YC; Hung HH; Lee HC
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380689
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway.
Wang SF; Chen MS; Chou YC; Ueng YF; Yin PH; Yeh TS; Lee HC
Oncotarget; 2016 Nov; 7(45):74132-74151. PubMed ID: 27708226
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Mitsiades CS
J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842
[No Abstract] [Full Text] [Related]
14. Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.
Pullarkat V; Meng Z; Tahara SM; Johnson CS; Kalra VK
Hemoglobin; 2014; 38(3):188-95. PubMed ID: 24670032
[TBL] [Abstract][Full Text] [Related]
15. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway.
Chen RS; Song YM; Zhou ZY; Tong T; Li Y; Fu M; Guo XL; Dong LJ; He X; Qiao HX; Zhan QM; Li W
Oncogene; 2009 Jan; 28(4):599-609. PubMed ID: 19015640
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells.
Du ZX; Yan Y; Zhang HY; Liu BQ; Gao YY; Niu XF; Meng X; Wang HQ
J Clin Endocrinol Metab; 2011 May; 96(5):E763-71. PubMed ID: 21346076
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor lactacystin enhances GSH synthesis capacity by increased expression of antioxidant components in an Nrf2-independent, but p38 MAPK-dependent manner in rat colorectal carcinoma cells.
Huseby NE; Ravuri C; Moens U
Free Radic Res; 2016; 50(1):1-13. PubMed ID: 26530909
[TBL] [Abstract][Full Text] [Related]
18. xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain.
Ungard RG; Linher-Melville K; Nashed MG; Sharma M; Wen J; Singh G
Mol Pain; 2019; 15():1744806918822185. PubMed ID: 30799686
[TBL] [Abstract][Full Text] [Related]
19. Mutation of ATF4 mediates resistance of neuronal cell lines against oxidative stress by inducing xCT expression.
Lewerenz J; Sato H; Albrecht P; Henke N; Noack R; Methner A; Maher P
Cell Death Differ; 2012 May; 19(5):847-58. PubMed ID: 22095285
[TBL] [Abstract][Full Text] [Related]
20. Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.
Brüning A; Rahmeh M; Friese K
Mol Oncol; 2013 Dec; 7(6):1012-8. PubMed ID: 23916134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
